With the goal of improving the therapeutic effectiveness, and overcoming drug resistance in melanoma, we combined vemurafenib, as well as SCH772984 with the Mcl-1 inhibitor S63845, and report here strongly enhanced effects on cell viability, apoptosis, and on proapoptotic pathways. The gene discussed is MCL1; the disease is melanoma.